Nanotherapeutics for treatment of pulmonary arterial hypertension

Victor Segura-Ibarra, Suhong Wu, Nida Hassan, Jose A. Moran-Guerrero, Mauro Ferrari, Ashrith Guha, Harry Karmouty-Quintana, Elvin Blanco

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Pulmonary arterial hypertension (PAH) is a devastating and fatal chronic lung disease. While current pharmacotherapies have improved patient quality of life, PAH drugs suffer from limitations in the form of short-term pharmacokinetics, instability, and poor organ specificity. Traditionally, nanotechnology-based delivery strategies have proven advantageous at increasing both circulation lifetimes of chemotherapeutics and accumulation in tumors due to enhanced permeability through fenestrated vasculature. Importantly, increased nanoparticle (NP) accumulation in diseased tissues has been observed pre-clinically in pathologies characterized by endothelial dysfunction and remodeled vasculature, including myocardial infarction and heart failure. Recently, this phenomenon has also been observed in preclinical models of PAH, leading to the exploration of NP-based drug delivery as a therapeutic modality in PAH. Herein, we discussed the advantages of NPs for efficacious treatment of PAH, including heightened therapeutic delivery to diseased lungs for increased drug bioavailability, as well as highlighted innovative nanotherapeutic approaches for PAH.

Original languageEnglish (US)
Article number890
Pages (from-to)890
JournalFrontiers in Physiology
Issue numberJUL
StatePublished - Jul 13 2018


  • Chronic lung disease
  • Drug delivery
  • Nanomedicine
  • Nanoparticles
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)


Dive into the research topics of 'Nanotherapeutics for treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this